Retacrit® (epoetin alfa-epbx)

aBL 125545

Retacrit® (epoetin alfa-epbx)

aBL 125545

U.S. License Holder:

Hospira / Pfizer

Date of License:

May-15-2018

Last Update:

Nov-15-2024

approved_indications FDA-Approved Indications

RETACRIT (epoetin alfa-epbx) is an erythropoiesis-stimulating agent (ESA) indicated for:

Treatment of anemia due to: (i) Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis; (ii) Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection; (iii) The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy;

Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery.

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In The E.U.

Retacrit (epoetin zeta) (Hospira) (December-2007)

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

IPR2013-00365

U.S. Patent No.
6,747,002 (Pharmacokinetic and Pharmacodynamic Modeling of Erythropoietin Administration)

Patent Owner
Janssen Pharmaceuticals, Inc.; Ortho-McNeil Pharmaceutical, Inc.

Petitioner(s)
Hospira, Inc.

§ 102 Challenge
Y: Claims 1-7, 12, 14-22, 24, 25, 27, 28

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Terminated Prior to Institution Decision

§ 103 challenge
Y: Claims 1-7, 12, 14-28

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Terminated Prior to Institution Decision

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (All Challenged Claims Disclaimed Prior to Institution Decision)

IPR Status
IPR Terminated Prior to Institution Decision (Patent Owner Disclaimed All Challenged Claims)

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:15-cv-00839 (D. Del.)

U.S. Patent Nos.
5,856,298 (Erythropoietin Isoforms) 5,756,349 (Production of Erythropoietin)

Plaintiffs
Amgen Inc.; Amgen Manufacturing, Ltd.

Defendants
Hospira, Inc.; GlaxoSmithKline LLC

Federal Circuit Appeal(s)
16-2179 19-1067 (Final Judgment) 19-1102 (Cross Appeal) (consolidated with 19-1067)

Status
District Court Case Terminated (Jury Verdict: '298 Patent Claims 24 and 27 Valid and Infringed, '349 Patent Not Infringed, Damages Award); Federal Circuit Appeal on Motion to Compel Dismissed and Petition for Writ of Mandamus Denied; Federal Circuit Appeal of Final Judgment Affirmed, Petition for En Banc Rehearing Denied

BPCIA
Y

Related News

Spotlight On: Biosimilar Litigations
April Breyer Menon Ha Kung Wong
October 31, 2024
What Do the Humira Biosimilar / Interchangeable Launches Mean for the Adalimumab Market?
April Breyer Menon Ha Kung Wong
August 7, 2023
Venable’s BiologicsHQ Monthly Injection – November 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
December 11, 2018
Venable’s BiologicsHQ Monthly Injection – May 2018
April M. Breyer Menon Joseph K. Yarsky Corinne E. Atton Robert S. Schwartz, Ph.D.
June 8, 2018
Amgen Obtains $70 Million Damages Award Against Hospira For Infringement Of Amgen’s Erythropoetin Patent
Christopher E. Loh
September 27, 2017

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha